Granules India is trading higher by 4% to Rs 454, extending its past four days rally on BSE, after the company said that its paracetamol facility at Bonthapally in Andhra Pradesh has passed an inspection by the US health regulator.
The stock opened at Rs 439 and touched a record high of Rs 467 on BSE. Till 1215 hours, a combined 325,377 shares changed hands on the counter on BSE and NSE.
In past one week, the stock has rallied over 15% from Rs 396 compared to a marginal 0.05% gain in benchmark S&P BSE Sensex.
On June 16, 2014 Granules India in a filing to the BSE said, the company's paracetamol facility has successfully passed a United States Food and Drug Administration (USFDA) inspection without any '483 observations'.
The facility has the world’s largest single active pharmaceutical ingredients (API) production line by volume.
An FDA Form 483 is issued to the firm's management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and other related acts.
The company’s four API facilities have successfully passed US FDA inspections in the past 12 months, it added.
The stock opened at Rs 439 and touched a record high of Rs 467 on BSE. Till 1215 hours, a combined 325,377 shares changed hands on the counter on BSE and NSE.
In past one week, the stock has rallied over 15% from Rs 396 compared to a marginal 0.05% gain in benchmark S&P BSE Sensex.
On June 16, 2014 Granules India in a filing to the BSE said, the company's paracetamol facility has successfully passed a United States Food and Drug Administration (USFDA) inspection without any '483 observations'.
The facility has the world’s largest single active pharmaceutical ingredients (API) production line by volume.
An FDA Form 483 is issued to the firm's management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and other related acts.
The company’s four API facilities have successfully passed US FDA inspections in the past 12 months, it added.
